Becton, Dickinson and Company (NYSE:BDX) Releases Earnings Results, Beats Expectations By $0.09 EPS

Becton, Dickinson and Company (NYSE:BDX) posted its quarterly earnings data on Thursday. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09, FiscalAI reports. Becton, Dickinson and Company had a return on equity of 14.84% and a net margin of 4.52%.The company had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the previous year, the firm posted $3.68 EPS. Becton, Dickinson and Company’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company updated its FY 2026 guidance to 12.620-12.720 EPS.

Here are the key takeaways from Becton, Dickinson and Company’s conference call:

• Third-quarter results exceeded expectations, with revenue of $5.0 billion up 4.4%, adjusted operating margin of 24.9%, and adjusted EPS of $3.23, up 4.9%.
• Growth was broad-based, with more than 90% of the portfolio delivering high-single-digit growth and double-digit expansion in biologic drug delivery, advanced patient monitoring, PureWick, advanced tissue regeneration, and pharmacy automation. BD also cited share gains and strong momentum from new product launches and targeted commercial investments.
• BD raised the midpoint of its fiscal 2026 adjusted EPS outlook to $12.62–$12.72 and expects revenue growth toward the high end of its low-double-digit FX-neutral range; currency is currently expected to provide an approximately 100-basis-point revenue tailwind.
• Management expects fiscal 2027 revenue growth to remain in the low-single-digit range, partly because the end of Alaris remediation creates an approximately 200-basis-point headwind. Tariffs reduced third-quarter margin by about 110 basis points, while oil, resin costs, and broader market conditions remain risks.
• Year-to-date free cash flow rose 45% to $1.7 billion, supporting $3.1 billion of shareholder returns, including approximately $2.3 billion in share repurchases and $0.9 billion in dividends.

Becton, Dickinson and Company Trading Down 0.3%

NYSE BDX traded down $0.54 on Friday, reaching $176.53. 1,851,934 shares of the company were exchanged, compared to its average volume of 1,849,473. The company has a current ratio of 0.87, a quick ratio of 0.55 and a debt-to-equity ratio of 0.55. The business’s fifty day moving average price is $154.37 and its 200 day moving average price is $162.51. The stock has a market capitalization of $48.64 billion, a P/E ratio of 53.17, a price-to-earnings-growth ratio of 12.53 and a beta of 0.19. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.4%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 106.33%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BDX. TD Cowen lifted their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research note on Wednesday. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Wells Fargo & Company upped their target price on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday. Royal Bank Of Canada increased their target price on shares of Becton, Dickinson and Company from $175.00 to $180.00 and gave the company a “sector perform” rating in a research report on Friday. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $210.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus price target of $185.00.

Becton, Dickinson and Company News Summary

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Quarterly results beat estimates. Fiscal Q3 revenue rose 5.4% year over year to approximately $5.0 billion, exceeding the $4.89 billion consensus estimate. Adjusted EPS of $3.23 also surpassed expectations of $3.14, with growth across BD’s core medical and interventional businesses. BD Reports Third Quarter Fiscal 2026 Financial Results
• Positive Sentiment: BD raised its fiscal 2026 outlook. The company now expects adjusted EPS of $12.62 to $12.72, above the prior outlook and the roughly $12.56 analyst consensus. Management also expects revenue growth toward the high end of its range and is targeting 90% free-cash-flow conversion. Year-to-date operating cash flow increased 33.3% to $2.1 billion, while free cash flow rose 44.6% to $1.7 billion. BD raises FY 2026 adjusted EPS guidance
• Positive Sentiment: Citigroup became more bullish. Citi raised its price target from $198 to $204 and assigned a “buy” rating, implying meaningful upside based on the cited reference price.
• Neutral Sentiment: Analyst views remain divided. Piper Sandler lifted its target to $175 but maintained a “neutral” rating, while Wells Fargo raised its target to $170 and kept an “equal weight” rating. Both targets remain below the cited share price, limiting the positive impact of the revisions.
• Negative Sentiment: Margins and earnings comparisons are concerns. Although revenue and adjusted earnings beat forecasts, margins declined and adjusted EPS fell from $3.68 in the year-earlier quarter. The stock’s elevated valuation may also make investors more sensitive to profitability pressure.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. The trade was a 7.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 5,189 shares of company stock valued at $765,661 over the last ninety days. Corporate insiders own 0.40% of the company’s stock.

Institutional Trading of Becton, Dickinson and Company

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Ausdal Financial Partners Inc. lifted its holdings in shares of Becton, Dickinson and Company by 4.0% during the 4th quarter. Ausdal Financial Partners Inc. now owns 2,544 shares of the medical instruments supplier’s stock worth $494,000 after acquiring an additional 97 shares during the period. Imprint Wealth LLC bought a new stake in Becton, Dickinson and Company in the third quarter valued at about $25,000. Bank of Jackson Hole Trust raised its position in Becton, Dickinson and Company by 28.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 649 shares of the medical instruments supplier’s stock worth $126,000 after purchasing an additional 145 shares in the last quarter. Prosperity Bancshares Inc bought a new position in Becton, Dickinson and Company during the fourth quarter worth about $29,000. Finally, Zions Bancorporation National Association UT lifted its stake in Becton, Dickinson and Company by 18.3% during the fourth quarter. Zions Bancorporation National Association UT now owns 962 shares of the medical instruments supplier’s stock worth $187,000 after purchasing an additional 149 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.